Combined intravitreal injection of triamcinolone acetonide and ranibizumab for age-related macular degeneration: study protocol for a randomized controlled trial

doi:10.3969/j.issn.2095-4344.0262

Abstract

Abstract:

BACKGROUND: Age-related macular degeneration is a condition that leads to the deterioration of the macula in the elderly, and is characterized by the presence of drusen and degenerative changes of the retinal pigment epithelium and choroidal capillaries. It is a major cause of blindness worldwide. The commonly used strategies, including antioxidant therapy and dilation of blood vessels, have shown undesired outcomes in clinical practice. Ranibizumab, an anti-vascular endothelial growth factor fusion protein, is an angiogenesis inhibitor that has been used to treat wet (neovascular) age-related macular degeneration; however, patients treated with ranibizumab are prone to develop endophthalmitis, rhegmatogenous retinal detachment, retinal tears, and iatrogenic traumatic cataract.
OJECTIVE: To determine the efficacy and safety of intravitreal injection of combination of triamcinolone acetonide and ranibizumab in the treatment of age-related macular degeneration in a randomized controlled trial.
METHODS: Eighty patients (160 eyes) with age-related macular degeneration admitted at Jingzhou Hospital Affiliated to Tongji Medical School of Huazhong University of Science and Technology, China will be recruited. These patients will be randomly assigned to control or treatment group at a 1:1 ratio. The patients in the control group will be treated with intravitreal injection of triamcinolone acetonide (0.1 mL, once daily), while those in the treatment group will be treated with combined intravitreal injection of triamcinolone acetonide (0.025 mL, once daily) and ranibizumab (0.05 mL, once a month). All patients will undergo continuous treatment for 3 months, followed by a 6-month follow-up. The primary outcome measure is foveal retinal thickness before and 6 months after treatment. The secondary outcome measures include best corrected visual acuity, intraocular pressure, quality of life scores before and 6 months after treatment, and the incidence of adverse events at 6 months after treatment. This study was approved by the Ethics Committee of the Jingzhou Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology, China (approval No. 20170338), and will be performed in accordance with the Declaration of Helsinki. The participants will be informed of the study protocol and procedures and asked to sign an informed consent. Participant recruitment will be initiated in January 2018. Sample and data collection will begin in January 2018 and end in June 2018. The analysis of outcome measures and the completion of trial will be in September 2018. The results of this study will be disseminated through presentations at scientific meetings and/or by publication in peer-reviewed journals. This trial was registered with the Chinese Clinical Trial Registry (registration No. ChiCTR-IOR-17013865).
DISCUSSION: We aim to confirm the safety and efficacy of the intravitreal injection of combination of triamcinolone acetonide and ranibizumab in the treatment of age-related macular degeneration.

中国组织工程研究杂志出版内容重点：组织构建；骨细胞；软骨细胞；细胞培养；成纤维细胞；血管内皮细胞；骨质疏松；组织工程

Key words: Tissue Engineering, Triamcinolone Acetonide, Macular Degeneration

CLC Number:

R318

Wei Fen, Xiao Xiu-lan. Combined intravitreal injection of triamcinolone acetonide and ranibizumab for age-related macular degeneration: study protocol for a randomized controlled trial[J]. Chinese Journal of Tissue Engineering Research, 2018, 22(16): 2583-2587.

Figures/Tables 1

References

[1] Bruè C, Pazzaglia A, Mariotti C, et al. Aflibercept as primary treatment for myopic choroidal neovascularisation: a retrospective study. Eye (Lond). 2016;30(1):139-145.

[2] Pacella E, Pacella F, Mazzeo F, et al. Effectiveness of vision rehabilitation treatment through MP-1 microperimeter in patients with visual loss due to macular disease. Clin Ter. 2012;163(6):e423-428.

[3] Antoniak K, Bienias W, Nowak JZ. Age-related macular degeneration--a complex genetic disease. Klin Oczna. 2008; 110(4-6):211-218.

[4] Oda H, Ohkawa S, Maeda K. Hemispatial visual defect in Alzheimer's disease. Neurocase. 2008;14(2):141-146.

[5] Kawagoe N, Takahashi M, Mandai M, et al. Peripherin/ RDS gene mutation in a patient with choroidal neovascularization. Nippon Ganka Gakkai Zasshi. 2007; 111(4):336-342.

[6] Xu L, Wang Y, Li Y, et al. Causes of blindness and visual impairment in urban and rural areas in Beijing: the Beijing Eye Study. Ophthalmology. 2006;113(7):1134.e1-11.

[7] Smith AG, Kaiser PK. Emerging treatments for wet age-related macular degeneration. Exp Opin Emerg Drugs. 2014;19(1):157-164.

[8] Vadot E, Durand L, Remy C. Late course of cicatricial chorioretinitis with paramacular localization. Bull Soc Ophtalmol Fr. 1979;79(1):15-16.

[9] Hu JY, Yan L, Chen YD, et al. Population-based survey of prevalence, causes, and risk factors for blindness and visual impairment in an aging Chinese metropolitan population. Int J Ophthalmol. 2017;10(1):140-147.

[10] Tong XW, Zhao R, Zou HD, et al. A prevalence investigation of blindness and vision impairment in 2009 in older adults of Dachang Blocks of Baoshan District, Shanghai, China. Zhonghua Yan Ke Za Zhi. 2011;47(9):785-790.

[11] Aujla JS. Replacing ranibizumab with bevacizumab on the Pharmaceutical Benefits Scheme: where does the current evidence leave us? Clin Exp Optom. 2012;95(5):538-540.

[12] Ma?gorzata F. Effectivity and safety of bevacizumab intravitreal injections for exudative age-related macular degeneration treatment-6 months observations. Klin Oczna. 2010;112(7-9):213-216.

[13] Kakkassery V, Winterhalter S, Joussen AM. Anti-VEGF inhibitors and their role in the treatment of diabetic macular oedema. Klin Monbl Augenheilkd. 2010;227(9):701-711.

[14] Akens MK, Hardisty MR, Wilson BC, et al. Defining the therapeutic window of vertebral photodynamic therapy in a murine pre-clinical model of breast cancer metastasis using the photosensitizer BPD-MA (Verteporfin). Breast Cancer Res Treat. 2010;119(2):325-333.

[15] Lubczyńska A, Kociecki J. Inhtravitreal triamcinolone acetonide injections in the treatment of cystoid macular edema due to the central or branch retinal vein occlusion.Klin Oczna. 2007;109(4-6):169-172.

[16] Lubczyńska A, Kociecki J. Intravitreal triamcinolone acetonide injections in treatment of cystoid macular edema due to diabetic maculopathy. Klin Oczna. 2007;109(4-6):165-168.

[17] Machalińska A, Paczkowska E, Pabin T, et al. Influence of ranibizumab on vascular endothelial growth factor plasma level and endothelial progenitor cell mobilization in age-related macular degeneration patients: safety of intravitreal treatment for vascular homeostasis. J Ocul Pharmacol Ther. 2011;27(5):471-475.

[18] Skelly A, Carius HJ, Bezlyak V, et al. Dispensing patterns of ranibizumab and aflibercept for the treatment of neovascular age-related macular degeneration: a retrospective cohort study in Australia. Adv Ther. 2017. doi: 10.1007/s12325-017-0624-6.

[19] Karagiannis D, Chatziralli I, Kaprinis K, et al. Location of submacular hemorrhage as a predictor of visual outcome after intravitreal ranibizumab for age-related macular degeneration. Clin Interv Aging. 2017;12:1829-1833.

[20] Kaya F. Change in choroidal thickness after intravitreal injection for treatment of neovascular age-related macular degeneration: ranibizumab versus aflibercept. J Fr Ophtalmol. 2017. doi: 10.1016/j.jfo.2017.04.014.

[21] 中华医学会眼科学会眼底病学组.老年性黄斑变性临床诊断标准[J].眼底病,1987,(3):封三.

[22] Zhang H, Lei C, Zhang TY, et al. Transcutaneous electri¬cal acupoint stimulation with different acupoint combinations on opioid consumption in patients undergoing off-pump coronary artery bypass grafting: study protocol for a randomized double-blind controlled trial. Clin Transl Degener Dis. 2016;1: 17-24.

[23] Wang Y. Chinese medicine packet plus wax therapy for periarthritis of the shoulder: study protocol for a multi-center randomized controlled trial. Clin Transl Degener Dis. 2016;1: 25-31.

[24] Ma N, Peng J, Guo QY. Local administration of enriched mononuclear cells, platelets and zoledronic acid for preventing collapse of the femoral head in the early stage of osteonecrosis: study protocol for a prospective randomized parallel-controlled clinical trial. Clin Transl Degener Dis. 2016; 1:32-37.